OraSure Technologies, Inc. (NASDAQ:OSUR) Stock Position Cut by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale lessened its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 84.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 4,875 shares of the medical instruments supplier’s stock after selling 25,878 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in OraSure Technologies were worth $40,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC grew its position in OraSure Technologies by 421.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 384,439 shares of the medical instruments supplier’s stock valued at $2,280,000 after buying an additional 310,715 shares in the last quarter. Pacer Advisors Inc. grew its position in OraSure Technologies by 122.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,403,333 shares of the medical instruments supplier’s stock valued at $19,707,000 after buying an additional 1,323,197 shares in the last quarter. Deutsche Bank AG grew its position in OraSure Technologies by 3.1% in the 3rd quarter. Deutsche Bank AG now owns 196,468 shares of the medical instruments supplier’s stock valued at $1,165,000 after buying an additional 5,875 shares in the last quarter. Vanguard Group Inc. grew its position in OraSure Technologies by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,396,285 shares of the medical instruments supplier’s stock valued at $32,000,000 after buying an additional 64,367 shares in the last quarter. Finally, Aviva PLC bought a new position in OraSure Technologies in the 3rd quarter valued at about $580,000. Institutional investors own 93.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Evercore ISI decreased their target price on shares of OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating for the company in a research report on Thursday, April 4th. Three research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, OraSure Technologies currently has an average rating of “Hold” and a consensus price target of $6.38.

OraSure Technologies Trading Up 0.6 %

NASDAQ:OSUR opened at $5.25 on Thursday. OraSure Technologies, Inc. has a twelve month low of $4.38 and a twelve month high of $8.45. The company has a 50-day moving average of $6.56 and a 200-day moving average of $6.82. The firm has a market cap of $401.68 million, a price-to-earnings ratio of 7.29 and a beta of 0.15.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.09. OraSure Technologies had a net margin of 13.23% and a return on equity of 14.50%. The company had revenue of $75.88 million during the quarter, compared to analyst estimates of $74.13 million. During the same quarter last year, the firm posted $0.21 EPS. The business’s revenue for the quarter was down 38.3% on a year-over-year basis. On average, research analysts forecast that OraSure Technologies, Inc. will post -0.11 earnings per share for the current year.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.